Polaris Group
TWSE:6550

Watchlist Manager
Polaris Group Logo
Polaris Group
TWSE:6550
Watchlist
Price: 31.5 TWD 1.94% Market Closed
Market Cap: NT$24.3B

Operating Margin

-4 213.3%
Current
Improving
by 12 412.5%
vs 3-y average of -16 625.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-4 213.3%
=
Operating Income
NT$-3B
/
Revenue
NT$71.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-4 213.3%
=
Operating Income
NT$-3B
/
Revenue
NT$71.1m

Peer Comparison

Country Company Market Cap Operating
Margin
KY
Polaris Group
TWSE:6550
24.3B TWD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 96% of companies in Cayman Islands
Percentile
4th
Based on 101 companies
4th percentile
-4 213.3%
Low
-16 672.6% — -2.9%
Typical Range
-2.9% — 10.1%
High
10.1% — 125.7%
Distribution Statistics
Cayman Islands
Min -16 672.6%
30th Percentile -2.9%
Median 2.9%
70th Percentile 10.1%
Max 125.7%

Polaris Group
Glance View

Market Cap
24.3B TWD
Industry
Biotechnology

In the competitive realm of biotechnology, Polaris Group has carved out a niche by focusing on the research and development of novel cancer therapeutics. Founded with a mission to bring innovative treatments to patients with unmet medical needs, the company has strategically positioned itself within the oncology sector. Polaris Group's approach is to harness the power of immunotherapy, aiming to develop solutions that enhance the immune system's ability to target and destroy cancer cells. This ambitious pursuit leverages cutting-edge technologies and a robust pipeline of investigational drugs, with particular emphasis on engineered drug compounds that can target specific pathways essential for cancer cell survival and proliferation. The key to Polaris Group's financial ecosystem is its revenue generation through strategic partnerships and collaborations with major pharmaceutical companies. By partnering with larger firms, Polaris is able to co-develop its breakthrough therapies, thus sharing the burden of development costs and risks. This model not only facilitates the advancement of their drug candidates but also offers potential revenue streams from milestone payments and royalties upon successful commercialization. Polaris’s business model underscores the significance of collaboration in biotech, where innovative ideas need both scientific expertise and considerable financial backing to transform into viable market solutions, ultimately contributing to the company's profitability and sustained growth in the competitive pharmaceutical landscape.

Intrinsic Value
1.49 TWD
Overvaluation 95%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-4 213.3%
=
Operating Income
NT$-3B
/
Revenue
NT$71.1m
What is Polaris Group's current Operating Margin?

The current Operating Margin for Polaris Group is -4 213.3%, which is above its 3-year median of -16 625.8%.

How has Operating Margin changed over time?

Over the last 3 years, Polaris Group’s Operating Margin has increased from -9 172.2% to -4 213.3%. During this period, it reached a low of -45 567.8% on Jun 30, 2023 and a high of -2 462.6% on Dec 31, 2024.

Back to Top